BioNTech says BNT113 plus pembrolizumab misses progression — free survival endpoint in AHEAD — MERIT trial
BioNTech disclosed first topline results from the AHEAD-MERIT Phase 2/3 trial of BNT113 with pembrolizumab in metastatic HPV16-positive head and neck cancer. The study missed its progression-free survival endpoint, weakening near-term prospects for the combination in this first-line setting. Overall survival remains th